Hypothesis

In aging neurons, bouts of neuronal activity generate mitochondrial ROS spikes that lead to reversible S‑glutathionylation of the OGG1 protein at a conserved cysteine residue (Cys253). This post‑translational modification transiently reduces OGG1’s glycosylase activity, creating a short‑lived “repair‑pause” window during which 8‑oxoG lesions can persist in mitochondrial DNA. When this pause becomes chronically extended due to sustained oxidative stress or impaired de‑glutathionylation (e.g., reduced glutaredoxin‑2 activity), 8‑oxoG accumulates preferentially in mtDNA, impairing neuronal bioenergetics and triggering calpain‑mediated neurite degeneration. Concurrently, microglia experiencing the same oxidative milieu exhibit nuclear 8‑oxoG accumulation because their OGG1 is less susceptible to glutathionylation (higher basal glutaredoxin expression), leading to persistent base excision repair attempts. The resulting toxic single‑strand breaks activate PARP1 and release AIF, driving microglial proinflammatory phenotypes.

Mechanistic Rationale

• Activity‑linked ROS: Neuronal firing elevates cytosolic Ca2+, stimulating mitochondrial NADH dehydrogenases and producing localized ROS bursts that can modify nearby proteins via thiol‑oxidation. Studies show that acute ROS can S‑glutathionylate DNA glycosylases, altering their affinity for damaged bases (see PMID: 29875412 for analogous effects on OGG1).
• Selective vulnerability: Neurons express lower levels of glutaredoxin‑2 compared with microglia, making their OGG1 more prone to inhibitory glutathionylation. Microglia, with robust antioxidant recycling, maintain OGG1 activity but suffer from unresolved repair intermediates when 8‑oxoG loads are high.
• Repair‑pause concept: Transient inhibition of OGG1 may be beneficial, allowing time for mitochondrial dynamics (e.g., fission/fusion) to segregate damaged genomes. Chronic inhibition, however, shifts the balance toward lesion accumulation.

Testable Predictions

1. Detection of S‑glutathionylated OGG1: In brain lysates from young vs. aged mice, immunoprecipitation of OGG1 followed by anti‑glutathione Western blot will show increased glutathionylation in aged tissue, correlating with elevated mtDNA 8‑oxoG levels.
2. Manipulating glutaredoxin‑2: Neuron‑specific overexpression of glutaredoxin‑2 in aged mice will reduce OGG1 glutathionylation, decrease mtDNA 8‑oxoG (measured by qPCR‑based lesion assay), and rescue neurite length in primary cortical cultures.
3. Microglia specificity: Microglial glutaredoxin‑2 knockdown will increase nuclear 8‑oxoG and PARP1 activation without affecting mtDNA lesion load, leading to heightened IL‑1β release upon LPS challenge.
4. Pharmacological mimic: Treatment of neurons with a cell‑permeable S‑glutathionylating agent (e.g., diamide at low dose) will transiently reduce OGG1 activity (measured by glycosylase assay) and increase mtDNA 8‑oxoG after repeated pulses, whereas a glutathionylation‑blocking mutant OGG1(C253S) will resist this effect.
5. Behavioral outcome: Aged mice receiving AAV‑mediated glutaredoxin‑2 overexpression in hippocampus will show improved performance in spatial memory tasks (Morris water maze) compared with controls receiving AAV‑GFP.

Experimental Approach

• Biochemical: Immunoprecipitate OGG1 from synaptosomal and mitochondrial fractions; probe with anti‑glutathione. Use mass spectrometry to confirm Cys253 modification.
• Cellular: Primary neurons and microglia isolated from WT and glutaredoxin‑2‑overexpressing mice; treat with glutamate to induce activity‑dependent ROS; measure OGG1 activity, 8‑oxoG (dot‑blot with specific antibody), and downstream effectors (calpain cleavage, PARP1 auto‑modification).
• In vivo: AAV‑glutaredoxin‑2 or AAV‑OGG1(C253S) delivered to hippocampus of 18‑month‑old mice; assess mtDNA 8‑oxoG, neuronal survival (NeuN+ counts), microglial state (Iba1/CD68), and cognitive performance.
• Controls: Use OGG1 knockout neurons to verify assay specificity; include N‑ethylmaleimide to block thiol reactions as a negative control.

Falsifiability

If elevated OGG1 S‑glutathionylation does not correlate with increased mtDNA 8‑oxoG in aged neurons, or if boosting glutaredoxin‑2 fails to reduce lesion load or improve cognition, the hypothesis would be refuted. Conversely, demonstrating that preventing glutathionylation (via C253S mutation) exacerbates neurodegeneration despite normal ROS levels would also falsify the proposed protective role of the repair‑pause.

Implications

This model links neuronal activity dynamics to DNA repair regulation, suggesting that therapeutic strategies aimed at modulating the redox state of OGG1 (e.g., targeted glutaredoxin activators or selective de‑glutathionylating agents) could mitigate mitochondrial dysfunction in neurodegeneration while avoiding the pitfalls of global OGG1 overactivation, which may increase toxic repair intermediates in microglia.